Experiment FindingsPDF Available

State of the Art H.E.L.P. Apheresis: Advances in Management of COVID-19, Long COVID, and Post-COVID-19 Vaccination Syndrome

Authors:
Beate Jaeger at Clinicum St Gerog Bad Aibling
Beate Jaeger
  • Clinicum St Gerog Bad Aibling
Abdul Mannan Baig at St George Hospital
Abdul Mannan Baig
Download file PDFDownload file PDF
Read file
Download citation

Abstract

This paper presents the findings of H.E.L.P. apheresis, which has proven to be a game changer and life saver for patients treated over 3 years now with COVID-19 and Long-COVID. Over the past three years, the practice of H.E.L.P. apheresis has faced the daunting challenge of managing hypercoagulable states in COVID-19 and Long COVID. Due to the association of multiple organ damage in COVID-19 and Long COVID with endothelial injury, procoagulant factor dominance, and ischemia-induced tissue injury, H.E.L.P. apheresis has distinctly demonstrated its advantage. It effectively lowers plasma levels of clotting factors, the spike protein, toxins, cytokines, and harmful lipids, thereby mitigating disease-related morbidity and mortality during the ongoing pandemic. Here, we provide compelling evidence showcasing the distinctive efficacy of this therapeutic modality both with and without anticoagulation drug therapy. This approach has proven beneficial for a significant cohort of patients experiencing Long-COVID and ME/CFS, addressing their needs across both the active and chronic phases of the disease. With the increasing prevalence of post-COVID-19 vaccination syndrome patients, H.E.L.P. apheresis has attained a new modality of significance to help this group of suffers, in addition to the COVID-19 and Long COVID categories.
Updated Author List-
1.docx
Content uploaded by Beate Jaeger
Author content
All content in this area was uploaded by Beate Jaeger on Apr 08, 2024
Content may be subject to copyright.
RG-Paper Edited-
1.docx
Content uploaded by Beate Jaeger
Author content
All content in this area was uploaded by Beate Jaeger on Dec 15, 2023
Content may be subject to copyright.
Beate Roxane Jaeger1*, Abdul Mannan Baig1, Renata Linkesch2, Julian Dowues1, Sergio
Presbitero Espinosa1, Martin Rössner1, Peter Holzhauer1, Friedrich Migeod1, Joachim
Gerlach3, Jochen Guck4, Martin Kräter5,Nikolaus Wick6, Hans Rausch7, Sandy Rosko8,
Usman Ali9, Anne McCloskey10, Kevin McCairn11, Deyana Uznnowa1,
Stephine Seneff12, Dietrich Seidel13.
* Correspondence:
Dr. Med. Beate Roxane Jaeger
Head of the Department of H.E.L.P Apheresis
Short title:
H.E.L.P Apheresis: Advances in Treatment of COVID-19-Related Hypercoagulability
Syndrome
Myocarditis, Coagulopathy, and Small Fibre, Sensory, and Multiple Cranial Nerve Neuropathy Complicating BNT162b2 Vaccination: A Case Report
Article
Full-text available
  • Feb 2024
SARS-CoV-2 vaccinations can lead to complications, including post-acute COVID-19 vaccination syndrome (PACVS). There has been no report of a patient with PACVS presenting with Guillain-Barre syndrome (GBS), myocarditis/pericarditis, immunodeficiency, or coagulopathy after the second BNT162b2 dose. The patient is a 51-year-old woman with chronic myopericarditis, coagulopathy due to factor-VIII increase and protein-S deficiency, GBS, and a number of other ocular, dermatological, immunological, and central nervous system abnormalities related to the second dose of the BNT172b2 vaccine. GBS manifested with mild, multiple cranial nerve lesions, small fibre neuropathy (SFN) affecting the autonomic system with postural tachycardia syndrome (POTS) and orthostatic hypotension, and sensory disturbances in the upper and lower limbs. PACVS was diagnosed months after onset, but despite the delayed diagnosis, the patient benefited from glucocorticoids, repeated HELP apheresis, and multiple symptomatic treatments. The case shows that SARS-CoV-2 vaccination can be complicated by PACVS manifesting as chronic myopericarditis, coagulopathy, GBS with predominant dysautonomia, and impaired immune competence, and that diagnosis of PACVS can be delayed for months. Delayed diagnosis of PACVS may result in a delay in appropriate treatment and the prolongation of disabling symptoms. Patients and physicians should be made aware of PACVS to improve diagnostic and therapeutic management in terms of patient and healthcare system costs.
View
ResearchGate has not been able to resolve any references for this publication.